Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231205490 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Kristen Wilhite und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Veterans Affairs Medical Center, Louisville, KY, USA. Hauptthemen laut MEDLINE: Pancreatitis, Diabetes Mellitus, Type 2, Thiazolidinediones, Incretins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Incretin therapies, comprised of the dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have been increasingly utilized for the treatment of type 2 diabetes (T2DM). Previous studies have conflicting results regarding risk of pancreatitis associated with these agents—some suggest an increased risk and others find no correlation. Adverse event reporting systems indicate that incretin therapies are some of the most common drugs associated with reports of pancreatitis.
Objectives
This study aimed to compare the odds of developing pancreatitis in veterans with T2DM prescribed an incretin therapy versus thiazolidinediones (TZDs: pioglitazone and rosiglitazone) within the Veterans Health Administration (VHA).
Methods
This was a retrospective cohort study analyzing veterans with T2DM first prescribed an incretin therapy or a TZD between January 1, 2011, and December 31, 2021. A diagnosis of pancreatitis within 365 days of being prescribed either therapy was counted as a positive case. Data was collected and analyzed utilizing VA’s Informatics and Computing Infrastructure (VINCI) and an adjusted odds ratio was calculated.
Results
The TZD cohort consisted of 42 912 patients compared with the incretin cohort of 304 811 patients. The TZD cohort had a pancreatitis incidence rate of 1.94 cases per 1000 patients. The incretin cohort had a incidence rate of 2.06 cases per 1000 patients. An adjusted odds ratio found no statistical difference of pancreatitis cases between the TZD and incretin cohorts (adjusted odds ratio [AOR] = 0.94, 95% CI [0.75, 1.18]). Conclusion and Relevance: This retrospective cohort study of national VHA data found a relatively low incidence of pancreatitis in both cohorts, and an adjusted odds ratio found no statistical difference of pancreatitis in patients prescribed an incretin therapy compared with a control group. This data adds to growing evidence that incretin therapies do not seem to be associated with an increased risk of developing pancreatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Veterans Affairs Medical Center, Louisville, KY, USA.
- Department of Pharmacy, Veterans Affairs Health Care System, Lexington, KY, USA.
ORCID-Profile: Kristen Wilhite
Zitieren
APA
Wilhite, K., Reid, J. M., & Lane, M. (2024). Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231205490
Vancouver
Wilhite K, Reid JM, Lane M. Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231205490
BibTeX
@article{Wilhite2024,
author = {Wilhite, Kristen and Reid, Jennifer Meyer and Lane, Matthew},
title = {Risk of Pancreatitis With Incretin Therapies Versus Thiazolidinediones in the Veterans Health Administration},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231205490}
}
EUVIMED